Cutaneous Toxicities With Amivantamab for Non-Small Cell Lung Cancer: A Practical Guide and Best Practices
Background:
Amivantamab is an epidermal growth factor receptor (EGFR) and MET bispecific antibody approved for certain patients with advanced non-small cell lung cancer with EGFR variant. Cutaneous toxicities are known on-target effects of EGFR inhibition.
Objectives:
This article describes the occurrence and management of cutaneous toxicities in patients whose disease progressed on platinum chemotherapy treated with amivantamab.
Methods:
Post hoc analysis evaluated incidence, severity, and time to first onset of rash and paronychia. Five nurses and advanced practice providers were interviewed.
Findings:
Of 380 patients, 296 (78%) experienced treatment-related rash and/or paronychia. Paronychia (43%), rash (36%), and dermatitis acneiform (35%) were most frequent, with scalp rash reported by 17%. Treatment modifications because of rash and paronychia were infrequent.
Insights
Amivantamab treatment for advanced non-small cell lung cancer can cause skin issues like rash and paronychia in most patients. Management strategies were evaluated, with treatment modifications being infrequent.
Area of Science:
- Oncology
- Dermatology
- Pharmacology
Background:
- Amivantamab is an EGFR and MET bispecific antibody for advanced non-small cell lung cancer (NSCLC) with EGFR variants.
- Cutaneous toxicities are known on-target effects of epidermal growth factor receptor (EGFR) inhibition.
Purpose of the Study:
- To describe the occurrence and management of skin toxicities in advanced NSCLC patients treated with amivantamab after platinum chemotherapy progression.
- To analyze the incidence, severity, and timing of rash and paronychia.
Main Methods:
- Post hoc analysis of patient data.
- Evaluation of rash and paronychia incidence, severity, and time to onset.
- Interviews with oncology nurses and advanced practice providers.
Main Results:
- 78% of 380 patients experienced treatment-related rash and/or paronychia.
- Most frequent toxicities included paronychia (43%), rash (36%), and acneiform dermatitis (35%).
- Scalp rash occurred in 17% of patients; treatment modifications were infrequent.
Conclusions:
- Cutaneous toxicities are common with amivantamab treatment in advanced NSCLC.
- Effective management strategies exist, as treatment modifications were infrequent.
- Understanding these toxicities is crucial for patient care and treatment adherence.
Related Concept Videos
01:30Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
01:26Toxic Reactions: Overview
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...